

Chair: Donal McLornan

Secretaries: Joanna Drozd-Sokolowska & Kavita Raj

Data management: Linda Koster, Laurien Baaij, Joe Tuffnell

Statisticians: Dirk-Jan Eikema, Luuk Gras, Simona Iacobelli


Ongoing studies - highlights

- MUD and MMUD with post-Cy in MF (Chalandon)
- MMRD donors for MF allo-HCT (Czerw)
- Use of AI for predicting outcome post allo-HCT for MF (Hernández-Boluda/Mosquera-Orgueira)
- Outcome following allo-HCT for CLL after venetoclax (van Gelder/Tournilhac)
- Outcome following allo-HCT for CLL after multiple PI (van Gelder/Tournilhac)
- Bridging therapy for CAR T cell therapy in PCD (Gagelmann/Merz)

MDS

Chair: Marie Robin, Vice Chair: Christof Scheid & Carmelo Gurnari & Francesco Onida


Number of first allogeneic HCT for MDS registered at EBMT per year



PCD

Chair: Patrick Hayden, Vice Chair: Meral Beksac & Stefan Schönland


Number of autologous HCT for MM registered by EBMT per year



CML

Chair: Yves Chalandon, Vice Chair: Guillermo Ortí & Hugues De Lavallade


Number of first allogeneic HCT for CML registered at EBMT per year



MPN

Chair: Juan Carlos Hernández-Boluda, Vice Chair: Tomasz Czerw & Nicola Polverelli & Giorgia Battipaglia


Number of first allogeneic HCT for MPN registered at EBMT per year



MDS/MPN

Chair: Marie Robin, Vice Chair: Christof Scheid & Carmelo Gurnari & Francesco Onida


Number of first allogeneic HCT for MDS/MPN registered at EBMT per year



PCD CAR-T

Chair: Nico Gagelmann, Vice Chair: Laurent Garderet


Number of CAR-T for MM registered at EBMT per year



CLL

Chair: Olivier Tournilhac, Vice Chair: Michel van Gelder

Number of first allogeneic HCT for CLL registered at EBMT per year



Published in 2024

Germline predisposition traits in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: a survey-based study and position paper based on an international expert panel on behalf of the Chronic Malignancies Working Party of the EBMT. – Gurnari *et al. Lancet Haematol.* 2023 Dec;10(12):e994-e1005. [https://doi.org/10.1016/S2352-3026\(23\)00265-X](https://doi.org/10.1016/S2352-3026(23)00265-X)

Graft-versus-Host Disease Prophylaxis with Post Transplant Cyclophosphamide in Chronic Myeloid Leukemia patients undergoing Allogeneic Hematopoietic Cell Transplant from either an Unrelated or Mismatched Related Donor: a comparative study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT) – Ortí *et al. Transplant Cell Ther.* 2024 Jan;30(1):93.e1-93.e12. <https://doi.org/10.1016/j.tict.2023.09.019>

Indication and management of allogeneic stem cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group – Kröger *et al. Lancet Haematol.* 2024 Jan;11(1):e62-e74. [https://doi.org/10.1016/S2352-3026\(23\)00305-8](https://doi.org/10.1016/S2352-3026(23)00305-8)

Allogeneic Haematopoietic Cell Transplantation for Therapy-related Myeloid Neoplasms arising following treatment for Lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT – Nabergoj *et al. Bone Marrow Transplant.* 2024 Jan 9. <https://doi.org/10.1038/s41409-023-02193-z>

Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT – Drozd-Sokolowska *et al. Haematologica.* 2024 Jan 11. <https://doi.org/10.3324/haematol.2023.284359>

Impact of Post-transplant cyclophosphamide (PTCy)-Based Prophylaxis in Matched Sibling Donor Allogeneic Haematopoietic Cell Transplantation for Patients with Myelodysplastic Syndrome: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT – Salas *et al. Bone Marrow Transplant.* 2024 Jan 22. <https://doi.org/10.1038/s41409-023-02159-1>

In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT – Beksac *et al. Bone Marrow Transplant.* 2024 Jan 31. <https://doi.org/10.1038/s41409-023-02160-8>

Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS - A study of the CMWP of the EBMT – Rovó *et al. Am J Hematol.* 2024 Feb;99(2):203-215. <https://doi.org/10.1002/ajh.27150>

Sequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT – Potter *et al. Bone Marrow Transplant.* 2024 Feb;59(2):224-231. <https://doi.org/10.1038/s41409-023-02111-3>

Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: a study on behalf of the Chronic Malignancies Working Party of the EBMT – Robin *et al. Br J Haematol.* 2024 Feb;204(2):715-718. <https://doi.org/10.1111/bjh.19214>

Allogeneic Hematopoietic Cell Transplantation for VEXAS Syndrome: Results of a Multicenter Study of the EBMT – Gurnari *et al. Blood Adv.* 2024 Feb 8;bloodadvances.2023012478. <https://doi.org/10.1182/bloodadvances.2023012478>

Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in Myelofibrosis: a study on behalf of the Chronic Malignancies Working Party of EBMT – Polverelli *et al. Am J Hematol.* 2024

Allogeneic hematopoietic stem-cell transplantation for patients with Richter Transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. – Gueze *et al. Bone Marrow Transplant.* 2024

The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed Multiple Myeloma: considerations on behalf of the Chronic Malignancies Working Party of the EBMT – Hwang *et al. Br J Haematol.* 2024